Target vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: TGT | $107B revenue 2024; #8 US retailer with 2,000+ stores; strong omnichannel fulfillment; 45% of sales in owned and exclusive brands; Target Circle loyalty 100M+ members
About
Target Corporation was founded in 1902 as Dayton Dry Goods Company in Minneapolis, Minnesota, and launched its discount retail concept under the Target brand in 1962, positioning itself from the outset as a more design-conscious and pleasant shopping alternative to conventional discount stores. The company's founding retail thesis — that price-sensitive consumers still care about aesthetics and store experience — became a durable competitive differentiator, capturing a middle-income customer segment that competitors like Walmart and Kmart did not fully serve. Target's core business model combines private-label and national-brand merchandise across apparel, home, electronics, grocery, and essentials in a large-format store built around a seamless in-store experience.\n\nTarget operates more than 2,000 stores across all 50 US states and has invested heavily in an omnichannel model that treats stores as fulfillment hubs for digital orders. Same-day services — Drive Up curbside pickup, in-store Order Pickup, and Shipt same-day delivery — now account for a significant and growing share of digital sales, leveraging store proximity rather than warehouse infrastructure. The Target Circle loyalty program has tens of millions of active members and serves as the primary data and personalization engine for the company's marketing and promotions strategy. Target also operates a media network, Roundel, which monetizes its first-party shopper data for brand advertising.\n\nTarget generated $107 billion in revenue in 2024, ranking as the eighth-largest US retailer with strong owned brands such as Cat & Jack, All in Motion, and Threshold. The company competes with Walmart, Amazon, and Costco across its broad merchandise mix. Target's combination of store density, same-day fulfillment capability, and consumer perception as a step above conventional discount retail gives it a defensible position in the US mass market.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.